Gene therapy for Parkinson's disease: still a hot topic?
作者信息
Kordower Jeffrey H
机构信息
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
出版信息
Neuropsychopharmacology. 2015 Jan;40(1):255-6. doi: 10.1038/npp.2014.235.
Abstract
摘要
相似文献
1
Gene therapy for Parkinson's disease: still a hot topic?帕金森病的基因治疗：仍是热门话题？
Neuropsychopharmacology. 2015 Jan;40(1):255-6. doi: 10.1038/npp.2014.235.
2
Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.帕金森病的基因治疗：神经退行性疾病的最新治疗方法。
Expert Rev Neurother. 2013 Jun;13(6):695-705. doi: 10.1586/ern.13.58.
3
Novel perspectives for Parkinson's disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets.帕金森病治疗的新视角：来自疾病病理生理学、诊断与实验工具以及分子靶点最新进展的见解
CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1083-5.
4
[New therapy approaches for Parkinson's disease].[帕金森病的新治疗方法]
Nervenarzt. 2017 Apr;88(4):391-396. doi: 10.1007/s00115-017-0299-x.
5
Optogenetic neuromodulation.光遗传学神经调节。
Int Rev Neurobiol. 2012;107:185-205. doi: 10.1016/B978-0-12-404706-8.00010-3.
6
Gene therapy for Parkinson's disease: do we have the cure?帕金森病的基因治疗：我们找到治愈方法了吗？
Lancet Neurol. 2010 Dec;9(12):1142-1143. doi: 10.1016/S1474-4422(10)70256-8.
7
Parkinson disease: Another player in gene therapy for Parkinson disease.帕金森病：帕金森病基因治疗中的另一个参与者。
Nat Rev Neurol. 2010 Jan;6(1):7-8. doi: 10.1038/nrneurol.2009.214.
8
Movement disorders: towards new therapies in Parkinson's disease.运动障碍：帕金森病新疗法的探索
Lancet Neurol. 2012 Jan;11(1):7-8. doi: 10.1016/S1474-4422(11)70284-8.
9
199 years of Parkinson disease - what have we learned and what is the path to the future?帕金森病199年——我们学到了什么以及未来之路何在？
J Neurochem. 2016 Oct;139 Suppl 1:3-7. doi: 10.1111/jnc.13733. Epub 2016 Aug 31.
10
Gene therapy in Parkinson's disease: dream or reality?帕金森病的基因治疗：梦想还是现实？
Neuroreport. 2002 May 7;13(6):743. doi: 10.1097/00001756-200205070-00002.
引用本文的文献
1
Bu-Yin-Qian-Zheng Formula Ameliorates MPP-Induced Mitochondrial Dysfunction in Parkinson's Disease via Parkin.补阴潜镇方通过帕金蛋白改善1-甲基-4-苯基吡啶离子诱导的帕金森病线粒体功能障碍。
Front Pharmacol. 2020 Dec 18;11:577017. doi: 10.3389/fphar.2020.577017. eCollection 2020.
2
Repairing the Brain: Gene Therapy.修复大脑：基因治疗。
J Parkinsons Dis. 2018;8(s1):S123-S130. doi: 10.3233/JPD-181485.
本文引用的文献
1
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.ProSavin，一种基于慢病毒载体的帕金森病基因治疗药物的长期安全性和耐受性：剂量递增、开放标签、1/2 期临床试验。
Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10.
2
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.帕金森病的疾病持续时间与黑质纹状体系统的完整性。
Brain. 2013 Aug;136(Pt 8):2419-31. doi: 10.1093/brain/awt192.
3
Trophic factor gene therapy for Parkinson's disease.神经营养因子基因治疗帕金森病。
Mov Disord. 2013 Jan;28(1):96-109. doi: 10.1002/mds.25344.
4
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.帕金森病 AADC 基因治疗的 1 期研究的长期评估。
Hum Gene Ther. 2012 Apr;23(4):377-81. doi: 10.1089/hum.2011.220. Epub 2012 Apr 10.
5
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.AAV2-GAD 基因治疗晚期帕金森病：一项双盲、假手术对照、随机试验。
Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.
6
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.AAV2-神经生长因子基因治疗帕金森病：一项双盲、随机、对照试验。
Lancet Neurol. 2010 Dec;9(12):1164-1172. doi: 10.1016/S1474-4422(10)70254-4. Epub 2010 Oct 20.
Zotero 插件